

CURE

VanEck
Genomics and Healthcare Innovators UCITS ETF

VanEck®

Fund Details

Base Currency	USD
Inception Date	02 September 2022
Domicile	Ireland
Net Assets	USD 6.9M
Shares Outstanding	360,000
Total Expense Ratio	0.35%
Product Structure	Physical (Full Replication)
UCITS Compliant	Yes
Rebalance Frequency	Semi-Annually
Distribution Frequency	None
Income Treatment	Reinvestment
Swiss Valor	121031038
ISA Eligibility	Yes
SIPP Available	Yes
Countries of Registration	AT, CH, DE, DK, ES, FI, FR, IE, IT, LU, NL, NO, PL, PT, SE, UK

Index Information

Index Provider	MarketVector Indexes GmbH
Index Type	Total Return Net
Currency	USD
Inception Date	06 Dec 2021
Rebalance Frequency	Semi-Annually
Bloomberg Ticker	MVFHCTR
Reuters Ticker	.MVFHCTR

Fund Data

Number of Holdings	53
Price/Earnings Ratio*	44.37
Price/Book Ratio*	3.50
Weighted Avg. MCap	USD 33.7B

* Last 12 Months

Country Breakdown

United States	84.40%
Germany	4.01%
China	3.69%
Australia	2.34%
Switzerland	1.68%
Japan	1.45%
Other/Cash	2.44%

Fund Description

The VanEck Genomics and Healthcare Innovators UCITS ETF (CURE) is a UCITS-compliant exchange-traded fund that invests in a portfolio of equity securities with the aim of providing investment returns that closely track the performance of the MVIS®Global Future Healthcare ESG Index.

The MVIS® Global Future Healthcare ESG Index is a global index that tracks the performance of companies that are involved in the genomic health care and electronic healthcare industries.

Performance History (%)

Month End as of 30 Jun 2024	1 MO*	3 MO*	YTD*	1 YR	3 YR	5 YR	10 YR	INCEPTION	ETF
ETF	1.88	-2.81	-3.78	-7.98	--	--	--	--	-2.59
MVFHCTR (Index)	1.89	-2.70	-3.60	-7.55	-14.81	--	--	--	-2.30

Source: VanEck

Past performance does not predict future returns.

Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Performance data for VanEck ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply. Returns may increase or decrease as a result of currency fluctuations.

*Periods greater than one year are annualised.

Top 10 Holdings

REGENERON PHARMACEUTICALS INC	8.30%
VERTEX PHARMACEUTICALS INC	7.99%
DEXCOM INC	6.37%
VEEVA SYSTEMS INC	5.89%
ALNYLAM PHARMACEUTICALS INC	5.76%
MODERNA INC	5.70%
ILLUMINA INC	5.36%
SAREPTA THERAPEUTICS INC	5.11%
NATERA INC	4.55%
INSULET CORP	3.57%
SUBTOTAL - TOP 10	58.61%
REMAINING HOLDINGS	41.21%
OTHER/CASH	0.19%
TOTAL	100.00%

For a complete up-to-date listing of Fund holdings, please visit www.vaneck.com

30 June 2024



Trading Information

30 June 2024

EXCHANGE	TRADING CURRENCY	ISIN	EXCHANGE TICKER	BLOOMBERG TICKER	REUTERS TICKER	SEDOL	IOPV SYMBOL
LONDON STOCK EXCHANGE	USD	IE000B9PQW54	CURE	CURE LN	CURE.L	BQFP700	CUREUSIV
LONDON STOCK EXCHANGE	GBP	IE000B9PQW54	CURG	CURG LN	CURG.L	BQFP711	CUREUSIV
DEUTSCHE BÖRSE	EUR	IE000B9PQW54	CURE	CURE GY	CURE.DE	BNG7JX1	CUREUSIV
SIX SWISS EXCHANGE	CHF	IE000B9PQW54	CURE	CURE SE	CURE.S	BNG7JZ3	CUREUSIV
BORSA ITALIANA	EUR	IE000B9PQW54	CURE	CURE IM	CURE.MI	BNG7JY2	CUREUSIV

Key Risks

Liquidity Risk: This risk exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all. This is a factor to consider before investing in a Genomics ETF.

Equity Market Risk: The prices of the securities in a Genomics ETF are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.

Industry or Sector Concentration Risk: The Fund's assets may be concentrated in one or more particular sectors or industries. A Genomics ETF may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund's assets were invested in a wider variety of sectors or industries.

For more information on risks, please see the "Risk Factors" section of the relevant Fund's prospectus, available on www.vaneck.com.

IMPORTANT INFORMATION

This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.

This information originates from VanEck (Europe) GmbH, which has been appointed as distributor of VanEck products in Europe by the Management Company VanEck Asset Management B.V., a UCITS Management Company incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). VanEck (Europe) GmbH, with registered address at Kreuznacher Str. 30, 60486 Frankfurt, Germany, is a financial services provider regulated by the Federal Financial Supervisory Authority in Germany (BaFin). The information is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice. VanEck (Europe) GmbH and its associated and affiliated companies (together "VanEck") assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. Information herein may change at any time; current data may differ from data quoted. Information provided by third party sources is believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. Brokerage or transaction fees may apply.

VanEck Asset Management B.V., the management company of VanEck Genomics and Healthcare Innovators UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. The value of the ETF assets may fluctuate heavily as a result of the investment strategy. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.

Investors must read the sales prospectus and key investor information before investing in a fund. These are available in English and the KIDs in certain other languages as applicable and can be obtained free of charge at www.vaneck.com or from the Management Company.

MVIS® Global Future Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH ("MarketVector"), Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Genomics and Healthcare Innovators UCITS ETF (the "ETF") is not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the ETF.

It is not possible to invest directly in an index.

All performance information is based on historical data and does not predict future returns.

Note: no guarantee can be provided that the fund will attain its objective. Investing is subject to risk, including the possible loss of principal.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

The IOPV is calculated by S&P Global Ltd.

© VanEck (Europe) GmbH